6 rezultatima
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity.
BACKGROUND OF THE INVENTION
The estrogen
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity.
BACKGROUND OF THE INVENTION
The estrogen
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity.
BACKGROUND OF THE INVENTION
The estrogen
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity.
BACKGROUND OF THE INVENTION
The estrogen
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity.
BACKGROUND OF THE INVENTION
The estrogen
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, and to compounds for inhibiting cytokines, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity, as well as to pharmaceutical compositions and methods